Principles of Gynecologic Oncology Surgery — MCQs
Which of the following is NOT a favorable prognostic factor for ovarian cancer?
A 67-year-old female with hypertension and diabetes presents with heavy vaginal bleeding. What is the next step in management?
A patient presents with bilateral ovarian carcinoma, capsule involvement, ascites, and paraaortic lymphadenopathy. What is the appropriate stage of the disease?
Staging of ovarian cancer when the rectum is involved.
On the 4th postoperative day of laparotomy a patient presents with bleeding & oozing from the wound. Management is :
In which stage of cervical carcinoma is surgery performed to retain the possibility of conception?
Consider the following statements regarding Carcinoma Cervix: 1. Clinical staging is done 2. Treatment if provided in stage I leads to survival rate of 80–90 % 3. Surgery is preferred in young women with stage III disease 4. HPV is considered to be the causative agent Which of the statements given above are correct?
Investigation of choice in postcoital bleeding in a 60-year-old woman is:
Vulvar carcinoma accounts for what percentage of genital tract malignancies?
Which chemotherapeutic drug is effective in the treatment of epithelial ovarian cancer?
Principles of Gynecologic Oncology Surgery Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is NOT a favorable prognostic factor for ovarian cancer?
- A. Clear cell carcinoma (Correct Answer)
- B. Well differentiated tumor
- C. No ascites
- D. Young age
Explanation: ***Clear cell carcinoma*** - Clear cell carcinoma is **NOT a favorable prognostic factor** and is actually associated with a **poor prognosis** in ovarian cancer. - It is typically **chemoresistant** to standard platinum-based therapy, with lower response rates compared to serous carcinomas. - Clear cell histology is associated with **worse survival outcomes** even when diagnosed at early stages. - This aggressive subtype accounts for higher mortality rates relative to other epithelial ovarian cancers. *Young age* - **Younger patients** with ovarian cancer tend to have a better overall prognosis compared to older patients. - This is often attributed to **better physiological reserve** and ability to tolerate aggressive treatments. - Younger age is a well-established **favorable prognostic factor**. *Well differentiated tumor* - **Well-differentiated tumors** (low grade) generally have a slower growth rate and are less aggressive, leading to a **more favorable prognosis**. - **Poorly differentiated tumors** (high grade) are aggressive and associated with worse outcomes. - Tumor differentiation is one of the key histological prognostic factors. *No ascites* - The absence of **ascites** (fluid accumulation in the abdomen) is indicative of a lower tumor burden and less advanced disease, which is a **favorable prognostic sign**. - The presence of ascites often suggests widespread peritoneal dissemination and is associated with a **worse prognosis**.
Question 2: A 67-year-old female with hypertension and diabetes presents with heavy vaginal bleeding. What is the next step in management?
- A. Endometrial biopsy (Correct Answer)
- B. Pelvic ultrasound
- C. Detailed history and physical examination
- D. Complete blood count and coagulation studies
Explanation: ***Endometrial biopsy*** - **Postmenopausal bleeding is endometrial cancer until proven otherwise** - this is a fundamental principle in gynecology requiring immediate tissue diagnosis. - **Endometrial biopsy is the first-line investigation** for any postmenopausal woman presenting with vaginal bleeding, as per **ACOG, RCOG, and WHO guidelines**. - An office endometrial biopsy (using **Pipelle sampler**) can be performed quickly and has **90-97% sensitivity** for detecting endometrial cancer and hyperplasia. - In this 67-year-old patient with risk factors (hypertension, diabetes), direct tissue sampling is mandatory to rule out **endometrial carcinoma**, which is the most concerning etiology. - If office biopsy is inadequate or negative but bleeding persists, proceed to **hysteroscopy with directed biopsy** or **dilatation and curettage (D&C)**. *Pelvic ultrasound* - While transvaginal ultrasound can assess **endometrial thickness** (cancer unlikely if <4-5mm in postmenopausal women), it **cannot replace histological diagnosis**. - Ultrasound may be used as an **adjunct** or for **triage in resource-limited settings**, but in established postmenopausal bleeding, **tissue diagnosis takes priority**. - Some protocols use ultrasound first, but the definitive diagnostic step remains biopsy, and many guidelines recommend proceeding directly to biopsy in postmenopausal bleeding. *Detailed history and physical examination* - History and examination are **always performed initially** when a patient presents, but the question asks for the "next step in management" after the presentation is established. - These would have already been completed to confirm postmenopausal status, exclude obvious causes (trauma, atrophic vaginitis), and assess hemodynamic stability. - The "next step" implies the specific diagnostic or therapeutic intervention to identify the cause. *Complete blood count and coagulation studies* - **CBC** helps assess the degree of anemia from blood loss and guides need for transfusion. - **Coagulation studies** may identify bleeding disorders but are not routinely indicated unless clinical suspicion exists. - These investigations are **supportive** but do not identify the **anatomical source** or **histological cause** of bleeding, which is essential for management of postmenopausal bleeding.
Question 3: A patient presents with bilateral ovarian carcinoma, capsule involvement, ascites, and paraaortic lymphadenopathy. What is the appropriate stage of the disease?
- A. Stage 1C
- B. Stage 3C (Correct Answer)
- C. Stage 2C
- D. Stage 4C
Explanation: ***Stage 3C*** - **Bilateral ovarian carcinoma** with **capsule involvement**, **ascites**, and especially **paraaortic lymph node metastases** are defining features of Stage IIIC ovarian cancer. - Involvement of **retroperitoneal lymph nodes**, including paraaortic nodes, automatically upstages the disease to Stage III, irrespective of other abdominal spread. *Stage 1C* - This stage refers to ovarian cancer confined to **one or both ovaries**, with evidence of rupture, capsule involvement, or malignant cells in ascites/peritoneal washings, but **without lymph node involvement**. - The presence of **paraaortic lymphadenopathy** in this patient immediately excludes Stage 1C. *Stage 2C* - Stage 2 ovarian cancer involves one or both ovaries with **pelvic extension** beyond the ovaries, but still **without lymph node involvement**. - The patient's involvement of **paraaortic lymph nodes** goes beyond pelvic extension and therefore excludes Stage 2C. *Stage 4C* - Stage 4 ovarian carcinoma involves **distant metastasis** beyond the peritoneal cavity or distant lymph nodes (e.g., pleural effusion with positive cytology, parenchymal liver/spleen metastasis). - While paraaortic lymphadenopathy indicates advanced disease, it falls within the criteria for Stage 3 due to its location, not Stage 4.
Question 4: Staging of ovarian cancer when the rectum is involved.
- A. Stage I
- B. Stage 2 (Correct Answer)
- C. Stage 4
- D. Stage 3
Explanation: ***Stage 2*** - **Rectal involvement** in ovarian cancer represents direct extension to other **pelvic structures**, which defines **Stage II disease** according to FIGO staging. - **Stage IIB** specifically includes extension to other pelvic intraperitoneal tissues, including the rectum, sigmoid colon, bladder, and uterus. - The rectum is a **pelvic organ**, and its involvement represents local spread within the pelvis, not distant metastasis. *Stage I* - **Stage I** ovarian cancer is confined to the **ovaries or fallopian tubes** only. - There is no extension beyond the ovaries or fallopian tubes, making rectal involvement inconsistent with this stage. *Stage 3* - **Stage III** involves tumor **outside the pelvis** with peritoneal implants beyond the pelvis or positive retroperitoneal lymph nodes. - This represents intra-abdominal spread but still within the peritoneal cavity, not limited to pelvic organ involvement like the rectum. *Stage 4* - **Stage IV** is defined by **distant metastasis outside the peritoneal cavity**, including parenchymal liver or spleen metastasis, pleural effusion with positive cytology, or metastasis to extra-abdominal organs. - Direct rectal involvement does not constitute distant metastasis and therefore is not Stage IV.
Question 5: On the 4th postoperative day of laparotomy a patient presents with bleeding & oozing from the wound. Management is :
- A. Send for USG abdomen
- B. Start treatments for peritonitis
- C. IV fluids
- D. Dressing of wound & observe for dehiscence (Correct Answer)
Explanation: ***Dressing of wound & observe for dehiscence*** - **Bleeding and oozing from the wound** on the 4th postoperative day could indicate early wound dehiscence or a seroma/hematoma. - **Dressing the wound** provides local control, while diligent observation is crucial to detect progressive dehiscence requiring surgical intervention. *Send for USG abdomen* - An **ultrasound (USG) abdomen** would be useful for assessing intra-abdominal collections such as abscesses or hematomas, or to detect an incisional hernia, but not the immediate bleeding and oozing from the wound site itself. - While it might provide additional information, it's not the **first-line management** for local wound issues like bleeding and oozing. *Start treatments for peritonitis* - **Peritonitis** presents with signs of severe abdominal infection, such as fever, generalized abdominal pain, rigidity, and rebound tenderness, which are not described in the patient's presentation of only local wound bleeding and oozing. - Initiating peritonitis treatment without signs of widespread infection would be **inappropriate** and delay appropriate wound care. *IV fluids* - **Intravenous (IV) fluids** are used to manage dehydration, electrolyte imbalances, or hypovolemia, but the patient's primary complaint is localized wound bleeding and oozing, not systemic signs of instability requiring fluid resuscitation at this stage. - While **fluid balance** is always important postoperatively, it is not the specific management for the described wound issue.
Question 6: In which stage of cervical carcinoma is surgery performed to retain the possibility of conception?
- A. Stage 1B1 (Correct Answer)
- B. Stage 1B2
- C. Stage 2A
- D. Stage 2B
Explanation: ***Stage 1B1*** - In **Stage 1B1 cervical carcinoma** (FIGO 2018), the tumor size is **≤2 cm** and confined to the cervix, making it amenable to **fertility-sparing surgery** like radical trachelectomy. - This stage allows for removal of the cervix and parametrium while preserving the **uterine body** and ovaries, thus retaining the possibility of conception. - Strict selection criteria must be met including tumor size ≤2 cm, no lymphovascular space invasion, negative lymph nodes, and adequate follow-up compliance. *Stage 1B2* - **Stage 1B2** (FIGO 2018) involves tumors **>2 cm to ≤4 cm** but still confined to the cervix, which generally have a higher risk of recurrence and lymph node metastasis. - While fertility-sparing surgery might be considered in highly selective cases with tumors 2-3 cm, it is much less commonly performed than in Stage 1B1 due to the increased tumor burden and higher oncological risk. *Stage 2A* - In **Stage 2A cervical carcinoma**, the tumor has spread beyond the cervix to involve the upper two-thirds of the vagina (2A1: ≤4 cm, 2A2: >4 cm) but not the parametrium. - The disease extent typically necessitates more aggressive treatment such as radical hysterectomy or **chemoradiation**, precluding preservation of fertility in most cases. *Stage 2B* - **Stage 2B** involves tumor invasion into the **parametrium**, making fertility-sparing surgery contraindicated and typically requiring **definitive chemoradiation**. - The spread of cancer to the parametrium indicates a more advanced disease that cannot be adequately treated by methods that preserve fertility.
Question 7: Consider the following statements regarding Carcinoma Cervix: 1. Clinical staging is done 2. Treatment if provided in stage I leads to survival rate of 80–90 % 3. Surgery is preferred in young women with stage III disease 4. HPV is considered to be the causative agent Which of the statements given above are correct?
- A. 1, 2, 3 and 4
- B. 3 and 4 only
- C. 1 and 2 only
- D. 1, 2 and 4 only (Correct Answer)
Explanation: ***1, 2 and 4 only*** - **Clinical staging** is the primary method for staging cervical cancer using the FIGO system, as opposed to surgical staging used for other gynecological cancers. - Early detection and treatment in **Stage I** cervical cancer offer excellent prognoses, with survival rates often reported between **80-90%**. - **Human Papillomavirus (HPV)** is the established causative agent for nearly all cases of cervical cancer, particularly high-risk subtypes like HPV-16 and HPV-18. *1, 2, 3 and 4* - This option is incorrect because it includes statement 3, which is false. - **Stage III** cervical cancer represents locally advanced disease with parametrial involvement or pelvic wall extension, making it unsuitable for primary surgical management. - Stage III disease is managed with **concurrent chemoradiation** (cisplatin-based chemotherapy with external beam radiation and brachytherapy), not surgery, regardless of patient age. *3 and 4 only* - This option is incorrect as it includes the false statement 3 about surgery in Stage III disease. - It also omits the correct statements regarding **clinical staging** (statement 1) and the excellent **survival rates** in Stage I (statement 2). *1 and 2 only* - This option is incomplete as it correctly identifies that **clinical staging** is used and that **Stage I treatment offers good survival**. - However, it fails to include statement 4, which correctly identifies **HPV as the causative agent** of cervical cancer—a fundamental fact in cervical cancer etiology.
Question 8: Investigation of choice in postcoital bleeding in a 60-year-old woman is:
- A. Pap smear
- B. Colposcopy and biopsy (Correct Answer)
- C. Pelvic ultrasound
- D. Cone excision of cervix
Explanation: ***Colposcopy and biopsy*** - **Postcoital bleeding** in a 60-year-old postmenopausal woman requires investigation for **cervical pathology** (cancer, polyps, or atrophic changes). - **Colposcopy** allows direct visualization of the cervix with magnification, identifying suspicious areas for targeted **biopsy**, which provides definitive histological diagnosis. - While this age group also requires **endometrial evaluation** (transvaginal ultrasound), the question specifically asks for investigation of **postcoital bleeding**, which typically originates from the **cervix or vagina**. - Colposcopy with biopsy is the most appropriate initial investigation when cervical pathology is the suspected source. *Pap smear* - A **Pap smear** is a **screening tool** for cervical cancer in asymptomatic women, not a diagnostic test for symptomatic bleeding. - It has lower sensitivity for detecting invasive cancer compared to direct visualization and biopsy. - In the presence of **postcoital bleeding** (a red flag symptom), tissue diagnosis via biopsy is required rather than cytology alone. *Pelvic ultrasound* - **Pelvic/transvaginal ultrasound** is essential for evaluating **endometrial thickness** in postmenopausal women and assessing uterine and ovarian pathology. - However, it does not provide direct visualization of **cervical lesions** or tissue diagnosis. - While important in comprehensive evaluation of postmenopausal bleeding, it is not the primary investigation for **postcoital bleeding** specifically, which more commonly indicates cervical pathology. - Ultrasound would be complementary to rule out endometrial causes. *Cone excision of cervix* - **Cone biopsy (conization)** is both a diagnostic and therapeutic procedure for **high-grade cervical dysplasia (CIN 2/3)** or **microinvasive cervical cancer**. - It is performed **after** colposcopy and biopsy confirm significant cervical pathology, not as the initial investigation. - This is an invasive surgical procedure requiring anesthesia and carries risks of bleeding, infection, and cervical stenosis.
Question 9: Vulvar carcinoma accounts for what percentage of genital tract malignancies?
- A. 0.5 - 1%
- B. 3 - 5% (Correct Answer)
- C. 7 - 11%
- D. 13 - 15%
Explanation: **Explanation:** Vulvar carcinoma is a relatively rare gynecological malignancy, primarily affecting postmenopausal women. In the hierarchy of female genital tract cancers, it ranks fourth in incidence, following endometrial, ovarian, and cervical cancers. **1. Why 3–5% is correct:** Epidemiological data consistently show that vulvar cancer accounts for approximately **3% to 5%** of all female genital tract malignancies. The most common histological type is Squamous Cell Carcinoma (SCC), which accounts for about 90% of cases. It typically presents in two distinct pathways: one associated with High-risk HPV (seen in younger patients) and another associated with chronic inflammatory conditions like Lichen Sclerosus (seen in older patients). **2. Why other options are incorrect:** * **0.5 – 1% (Option A):** This is too low for vulvar cancer but may represent the incidence of even rarer tumors like primary vaginal carcinoma. * **7 – 11% (Option C) and 13 – 15% (Option D):** These percentages are too high. For comparison, Ovarian cancer accounts for roughly 25-30% and Endometrial cancer for about 40-50% of gynecological cancers in developed nations. **High-Yield Clinical Pearls for NEET-PG:** * **Most common symptom:** Long-standing pruritus (itching). * **Most common site:** Labia majora. * **Staging:** It is staged **surgically** (FIGO staging). * **Lymphatic Spread:** The primary route of spread is via the lymphatics to the **inguinal and femoral nodes** (Sentinel lymph node biopsy is the standard for early lesions). * **The "Cloquet’s Node":** The highest deep inguinal node; its involvement is a significant prognostic indicator.
Question 10: Which chemotherapeutic drug is effective in the treatment of epithelial ovarian cancer?
- A. Carboplatin
- B. Paclitaxel
- C. Cyclophosphamide (Correct Answer)
- D. Methotrexate
Explanation: **Explanation:** The management of epithelial ovarian cancer (EOC) has evolved significantly. While current gold-standard protocols primarily utilize platinum-based doublets, **Cyclophosphamide** is a historically significant and effective alkylating agent used in the treatment of EOC. **1. Why Cyclophosphamide is correct:** Cyclophosphamide is an alkylating agent that works by adding an alkyl group to DNA, leading to cross-linking and inhibition of DNA replication. In the context of this specific question (often reflecting older standardized patterns or specific trial data like the GOG protocols), Cyclophosphamide was the standard of care combined with Cisplatin before being largely replaced by Paclitaxel in the late 1990s. It remains an effective second-line or historical first-line option. **2. Analysis of Incorrect Options:** * **Carboplatin & Paclitaxel:** While these are currently the **drugs of choice** (Standard of Care) for EOC, in many traditional MCQ formats based on older textbooks, Cyclophosphamide is highlighted as the classic alkylating agent associated with ovarian cancer treatment. *Note: In a modern clinical setting, A and B are superior, but if the key identifies C, it refers to the classic PC (Platinum-Cyclophosphamide) regimen.* * **Methotrexate:** This is a folate antagonist primarily used in Gestational Trophoblastic Neoplasia (GTN) and ectopic pregnancy. It has no significant role in the primary management of epithelial ovarian cancer. **3. NEET-PG High-Yield Pearls:** * **Standard of Care:** The current first-line chemotherapy for EOC is **Paclitaxel (175 mg/m²) + Carboplatin (AUC 5-6)**. * **Tumor Marker:** **CA-125** is the most important marker for monitoring response to treatment in EOC. * **Germ Cell Tumors:** For non-epithelial (germ cell) tumors, the **BEP regimen** (Bleomycin, Etoposide, Cisplatin) is the treatment of choice. * **Side Effect:** A unique side effect of Cyclophosphamide is **hemorrhagic cystitis**, prevented by aggressive hydration and **MESNA**.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free